The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase Ib trial of acalabrutinib + rituximab with or without lenalidomide in R/R follicular lymphoma
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase Ib trial of the bruton tyrosine kinase (BTK) inhibitor, acalabrutinib, plus rituximab and lenalidomide in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The efficacy of acalabrutinib was reported to improve when combined with rituximab and lenalidomide, and adverse events were infrequent and low-grade. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Hutchinson MediPharma: Consultancy; ADC Therapeutics: Consultancy, Research Funding; TG Therapeutics: Consultancy; Kite Gilead: Consultancy; Astrazeneca Acerta: Research Funding; ALX Oncology: Research Funding; Sobi: Research Funding; Roche Genentech: Consultancy.
